CANDEL THERAPEUTICS INC. - COMMON STOCK

4,9500

25-апреля-25 11:41:24

15 мин. задержка

Акции

-0,0500

-1,00%

Сегодняшний диапазон

4,8000 - 5,0250

ISIN

N/A

Источник

NASDAQ

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

23 апр 2025 16:05:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

01 апр 2025 08:01:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

26 мар 2025 16:05:18 Источник Nasdaq GlobeNewswire
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

20 мар 2025 08:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board

18 мар 2025 08:00:46 Источник Nasdaq GlobeNewswire
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

13 мар 2025 16:15:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

25 фев 2025 08:00:14 Источник Nasdaq GlobeNewswire
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

13 янв 2025 08:00:05 Источник Nasdaq GlobeNewswire
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

16 дек 2024 16:01:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Announces Pricing of Public Offering

12 дек 2024 23:00:53 Источник Nasdaq GlobeNewswire
Candel Therapeutics Announces $80 Million Proposed Public Offering

12 дек 2024 16:51:06 Источник Nasdaq GlobeNewswire
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

11 дек 2024 07:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

14 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024

07 ноя 2024 08:00:01 Источник Nasdaq GlobeNewswire
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

05 ноя 2024 09:00:32 Источник Nasdaq GlobeNewswire
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)

28 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting

04 окт 2024 09:00:45 Источник Nasdaq GlobeNewswire
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

03 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

13 авг 2024 08:00:01 Источник Nasdaq GlobeNewswire
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

18 июн 2024 08:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.